Recent studies have suggested that metabolites involving lipid, BAs, and amino acid pathways may contribute to predict response of anti-TNF therapy in adult IBD.24,26 Bjerrum et al.53 found distinct fecal metabolome profiles between IBD patients with different IFX outcomes, however, no applicable response biomarkers could be identified. The gene discussed is TNF; the disease is inflammatory bowel disease.